Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudeep PharmaBOM:544619 -1.10%18 PS Ratio is 20.38 as of Aug. 04, 2026, which is 28% above its 10-year median of 15.96. GuruFocus rates BOM:544619 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 954 Drug Manufacturers companies, Sudeep Pharma ranks worse than 94.44% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sudeep Pharma's share price is ₹868.55.
Sudeep Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹42.61. Hence, Sudeep Pharma's PS Ratio for today is 20.38.
Good Sign:
Sudeep Pharma Ltd stock PS Ratio (=14.43) is close to 1-year low of 13.61.
The historical rank and industry rank for Sudeep Pharma's PS Ratio or its related term are showing as below:
BOM:544619'
s PS Ratio Range Over the Past 10 Years
Min: 13.61 Med: 15.96 Max: 21.14
Current: 21.14
During the past 4 years, Sudeep Pharma's highest PS Ratio was 21.14. The lowest was 13.61. And the median was 15.96.
BOM:544619's PS Ratio is ranked worse than 94.44% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.305
vs BOM:544619: 21.14
During the past 12 months, the average Revenue per Share Growth Rate of Sudeep Pharma was 30.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 14.90% per year.
During the past 4 years, Sudeep Pharma's highest 3-Year average Revenue per Share Growth Rate was 14.90% per year. The lowest was 14.90% per year. And the median was 14.90% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Sudeep Pharma PS Ratio Related Terms
Sudeep Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Sudeep Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sudeep Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudeep Pharma PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sudeep Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Sudeep Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Sudeep Pharma's Share Price of today is ₹868.55. Sudeep Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹42.61.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Sudeep Pharma (BOM:544619) has a PS Ratio of 20.38 as of Aug. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sudeep Pharma and its competitors. This is 28% above median its historical median of 15.96. Over the past decade, Sudeep Pharma's PS Ratio has ranged from 13.61 to 21.14. According to the industry distribution chart, Sudeep Pharma ranks #901 out of 954 companies in the Drug Manufacturers industry, placing it in the top 94.4%.
Is Sudeep Pharma's PS Ratio too high?
Sudeep Pharma's current PS Ratio of 20.38 is 28% above median its 10-year median of 15.96. Over the past 10 years, this metric has ranged from a low of 13.61 to a high of 21.14. The Drug Manufacturers industry median PS Ratio is 2.31. Sudeep Pharma's value of 20.38 is 784.2% above this industry median. Based on the distribution chart, Sudeep Pharma ranks #901 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sudeep Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sudeep Pharma ranks #901 out of 954 companies for PS Ratio. This places Sudeep Pharma in the lower half of its industry. The industry median PS Ratio is 2.31. Sudeep Pharma's value of 20.38 is 784.2% above this benchmark. Historically, Sudeep Pharma's own PS Ratio has ranged from 13.61 to 21.14 over the past decade. While the company's 10-year median is 15.96 vs. the industry median of 2.31, Sudeep Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.31, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sudeep Pharma's current PS Ratio of 20.38 is 784.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sudeep Pharma and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudeep Pharma's current PS Ratio is 20.38, which is 28% above median its own 10-year median of 15.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current PS Ratio of 20.38. The current PS Ratio is 20.38, which is 28% above median its 10-year median of 15.96 and 784.2% above the Drug Manufacturers industry median of 2.31. Sudeep Pharma's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current PS Ratio is 20.38 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
18GF Score
Get the complete analysis for BOM:544619
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544619 has been successfully added to your 
